Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.
1. A method for treating a female undergoing embryo transfer comprising administering to the female an oxytocin receptor antagonist (1) only during a time
a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle;
b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle;
c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or
d) between day 6 and day 9 of a luteal phase support;
or (2) only on the day of transfer of an embryo, wherein the transferred embryo is a blastocyst-stage embryo.
2. The method of claim 1 , further comprising transferring an embryo into the uterus, the uterine cavity or the fallopian tubes of the female.
3. The method of claim 2 , wherein the antagonist is administered to the female between 2 hours prior to and 2 hours after embryo transfer.
4. The method of claim 1 , wherein the antagonist is administered to the female at day 5 post oocyte retrieval.
5. The method of claim 1 , wherein the luteal phase support comprises supplementation with progesterone, estradiol and progesterone, human chorionic gonadotropin, a progestin and/or a gonadatropin releasing hormone (GnRH) agonist.
6. The method of claim 1 , wherein the transferred embryo is a cleavage-stage embryo and the antagonist is administered to the female only during a time
a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle;
b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle;
c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or
d) between day 6 and day 9 of a luteal phase support.
7. The method of claim 6 , wherein the cleavage-stage embryo is a day 2 or day 3 post-fertilization embryo.
8. The method of claim 1 , wherein the blastocyst-stage embryo has an expansion and hatching status of 3, 4, 5, or 6.
9. The method of claim 1 , wherein the antagonist is a selective oxytocin receptor antagonist or a vasopressin/oxytocin receptor antagonist.
10. The method of claim 9 , wherein the antagonist is barusiban.
11. The method of claim 10 , wherein 30-80 mg of barusiban is administered.
12. The method of claim 1 , wherein a blastocyst-stage embryo is transferred to the female, and wherein barusiban is administered to the female on the same day as embryo transfer.
13. The method of claim 12 , wherein a first dose of 40 mg of barusiban is subcutaneously administered to the female 45 minutes prior to embryo transfer and 10 mg of barusiban is subcutaneously administered to the female 60 minutes after the first dose of barusiban.
14. A method of implanting an embryo in a female subject, said method comprising transferring an embryo into the uterus, the uterine cavity or the fallopian tubes of a female and administering to the female an oxytocin receptor antagonist (1) only during a time
a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle;
b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle;
c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or
d) between day 6 and day 9 of a luteal phase support;
or (2) only on the day of transfer of an embryo, wherein the transferred embryo is a blastocyst-stage embryo.
15. The method of claim 14 , wherein the antagonist is administered to the female at day 5 post oocyte retrieval.
16. The method of claim 14 , wherein the luteal phase support comprises supplementation with progesterone, estradiol and progesterone, human chorionic gonadotropin, a progestin and/or a gonadatropin releasing hormone (GnRH) agonist.
17. The method of claim 14 , wherein the transferred embryo is a cleavage-stage embryo and the antagonist is administered to the female only during a time
a) between day 6 following luteinizing hormone (LH) surge (LH+6) and day 9 following LH surge (LH+9) of a natural ovulation cycle;
b) between day 6 following human chorionic gonadotropin (hCG) administration (hCG+6) and day 9 following hCG administration (hCG+9) of an induced ovulation cycle;
c) between day 6 and day 7 of a luteal phase support following oocyte retrieval; or
d) between day 6 and day 9 of a luteal phase support.
18. The method of claim 14 , wherein the antagonist is a selective oxytocin receptor antagonist or a vasopressin/oxytocin receptor antagonist.
19. The method of claim 18 , wherein the antagonist is barusiban.
20. The method of claim 19 , wherein 30-80 mg of barusiban is administered.
21. The method of claim 19 , wherein the transferred embryo is a blastocyst-stage embryo, and wherein barusiban is administered to the female on the same day as embryo transfer.
22. The method of claim 21 , wherein a first dose of 40 mg barusiban is subcutaneously administered to the female 45 minutes prior to embryo transfer and 10 mg barusiban is subcutaneously administered to the female 60 minutes after the first dose of barusiban.